Performance is underpinned by the INFINITY dataset, which leverages over 1 million exomes and genomes to provide a competitive moat in diagnostic accuracy and turnaround times. The company is shifting from a specialist-only focus to mainstream medicine, targeting general pediatricians to address the five-year average diagnostic odyssey for rare diseases. Growth is driven by a 'stacking effect' where foundational markets (genetics and neurology) provide a stable base while expansion markets (NICU, pren ...